Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy

Shobaki, Nour; Sato, Yusuke; Suzuki, Yuichi; Okabe, Nana; Harashima, Hideyoshi

doi:10.1016/j.jconrel.2020.07.001

Cited by 80 publications

(42 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ester motifs are easy to incorporate, chemically stable, bio-cleavable, and their biodegradation kinetics can be effectively controlled [ [189] , [190] , [191] ]. Some examples of ester-based biodegradable lipids include L319 [ 179 , 189 ], YSK12-C4 [ 192 ], CL4H6 [ 193 ], and the Moderna proprietary lipid series [ 126 , 194 ], and Acuitas proprietary lipid series [ 195 ] ( Fig. 6 D).…”

Section: Materials For Mrna Deliverymentioning

confidence: 99%

Self-assembled mRNA vaccines

Kim

Eygeris

Gupta

et al. 2021

Advanced Drug Delivery Reviews

340

383

View full text Add to dashboard Cite

Section: Materials For Mrna Deliverymentioning

confidence: 99%

Self-assembled mRNA vaccines

Kim

Eygeris

Gupta

et al. 2021

Advanced Drug Delivery Reviews

340

383

View full text Add to dashboard Cite

“…223 Recently, siRNA-loaded nanoparticle mediated silencing of signal transducer and activator of transcription 3 and hypoxia-inducible factor 1 a prevented TAM-mediated angiogenesis and decreased tumour size. 224 In vitro, repolarization has also been achieved with nanoparticle delivery of plasmid DNA encoding the IL-12 gene 225 and with overexpression of microRNA-155 in triple negative breast cancer TAMs. 226 Another approach delivers CRISPR-Cas9 gene editing machinery into MФ: knock out of signal regulatory protein a, which engages CD47 on cancer cells and prevents phagocytosis, significantly increased MФ targeting of osteosarcoma cells in vitro.…”

Section: Intracellular Pathway Targetingmentioning

confidence: 99%

Macrophage reprogramming for therapy

et al. 2021

View full text Add to dashboard Cite

Dysfunction of the immune system underlies a plethora of human diseases, requiring the development of immunomodulatory therapeutic intervention. To date, most strategies employed have been focusing on the modification of T lymphocytes, and although remarkable improvement has been obtained, results often fall short of the intended outcome. Recent cutting-edge technologies have highlighted macrophages as potential targets for disease control. Macrophages play central roles in development, homeostasis and host defence, and their dysfunction and dysregulation have been implicated in the onset and pathogenesis of multiple disorders including cancer, neurodegeneration, autoimmunity and metabolic diseases. Recent advancements have led to a greater understanding of macrophage origin, diversity and function, in both health and disease. Over the last few years, a variety of strategies targeting macrophages have been developed and these open new therapeutic opportunities. Here, we review the progress in macrophage reprogramming in various disorders and discuss the potential implications and challenges for macrophage-targeted approaches in human disease.

show abstract

“…Since the major challenge for siRNA-based therapeutics is their delivery, Shobaki et al prepared LPNs by mimicking the envelope-type viruses that followed a novel packaging strategy. 59 The LPNs were composed of CL4H6 lipid (a pH-sensitive cationic lipid), in addition to cholesterol (chol) and PEGylated-lipids, which led to a high EE of siRNA (> 90%). Furthermore, the intravenously injection of siRNA-loaded LPNs into the institute of cancer research mice, the LNPs modified with 1,2-distearoylrac-glycero-3-methylpolyoxyethylene (DSG-PEG 2000) at a level of 1 mol-% of total lipid resulted in minimal siRNA leakage and higher integrity and stability of the LNP in the blood circulation.…”

Section: Macrophagesmentioning

confidence: 99%

Nanoparticle‐mediated siRNA delivery systems for cancer therapy

Gao

Chen

Santos

2021

VIEW

View full text Add to dashboard Cite

The small interfering RNA (siRNA)-based therapeutics have raised great attention since the first RNA interference (RNAi)-derived drug, patisiran, was approved by the US Food and Drug Administration, which represented a landmark in the field of gene therapy. Given the properties of interfering diseaseassociated gene expression, RNAi machinery is regarded as an essential factor for preparing precise medicine. However, over the past few years, siRNA drugs are undergoing a period of clinical translation, in which the major hurdle is the limited efficient delivery strategies. Therefore, this mini-review mainly focuses on describing the state-of-the-art of the nanoscale platforms for delivering siRNA payloads, also addressing their applications in cancer therapy. Finally, the status of siRNA drugs under clinical trials is discussed, providing a comprehensive understanding on the field of oligonucleotide-mediated therapeutics.

show abstract

Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy

Cited by 80 publications

References 78 publications

Self-assembled mRNA vaccines

Self-assembled mRNA vaccines

Macrophage reprogramming for therapy

Nanoparticle‐mediated siRNA delivery systems for cancer therapy

Contact Info

Product

Resources

About